Valuation : Carmat SA

Market Cap 6.15M 7.13M 5.8M 5.28M 9.87M 681M 9.96M 69.1M 26.58M 347M 26.79M 26.2M 1.1B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 68.78M 55.93M 50.91M 95.16M 6.57B 96.04M 666M 256M 3.34B 258M 253M 10.63B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.0962
0.16
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 01/09/2016
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 02/01/2017
Director/Board Member 79 20/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/3/25 Sell

Chairman

1,343,333 2.3347%
13/3/25 Buy

Chairman

1,343,333 2.3347%
29/5/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-24.77%-98.53% 7.08M
-1.95%-13.51%-31.25%-6.75% 106B
0.00%-3.48%-28.54%-3.89% 11.68B
-5.23%-5.10%+87.42%+129.07% 10.6B
-2.18%-4.26%-54.99%-71.10% 4.08B
-1.02%-2.40%-28.53%+34.56% 2.42B
-3.34%-8.43% - - 1.88B
+2.47%+8.01%-16.39%-69.66% 1.92B
-1.11%-1.91%-23.15%-28.32% 1.55B
Average -1.37%-2.50%-15.03%-14.33% 15.53B
Weighted average by Cap. -1.97%-9.09%-22.26%+1.63%

Financials

2023 2024
Net sales 3.84M 4.45M 3.62M 3.3M 6.16M 425M 6.22M 43.14M 16.59M 216M 16.73M 16.36M 688M 7.34M 8.53M 6.93M 6.31M 11.8M 814M 11.9M 82.57M 31.76M 414M 32.01M 31.31M 1.32B
Net income -53.87M -62.54M -50.86M -46.29M -86.52M -5.97B -87.32M -606M -233M -3.04B -235M -230M -9.66B -51.4M -59.66M -48.52M -44.16M -82.55M -5.7B -83.31M -578M -222M -2.9B -224M -219M -9.22B
Net Debt 49.64M 57.62M 46.86M 42.65M 79.72M 5.5B 80.46M 558M 215M 2.8B 216M 212M 8.9B 53.1M 61.64M 50.13M 45.63M 85.29M 5.89B 86.07M 597M 230M 2.99B 231M 226M 9.53B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!